Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?
- Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 10/30/2024
|
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
- Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
- 10/01/2024
|
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
- Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and Arcturus Therapeutics' commitment to advancing COVID-19 vaccine innovation to protect public health. WALTHAM, Mass.
- 09/30/2024
|
Here's Why Investors Should Invest in Arcturus Stock Now
- Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
- 09/16/2024
|
New Strong Buy Stocks for September 13th
- ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
- 09/13/2024
|
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
- Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®, the world's first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, was approved for adults 18 years of age and older in November 2023 The updated sa-mRNA COVID-19 vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants Meiji Seika Pharma, CSL's exclusive partner in Japan, will begin vaccine distribution in time for the October COVID-19 vaccination campaign CSL and Arcturus Therapeutics' partnership delivers on the promise to advance innovative vaccine technology for viral respiratory diseases KING OF PRUSSIA, Pa. and SAN DIEGO , Sept.
- 09/13/2024
|
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 216.4% in Arcturus Therapeutics (ARCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 09/02/2024
|
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
- Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 08/23/2024
|
New Strong Buy Stocks for August 23rd
- RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.
- 08/23/2024
|
High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
- Arcturus is close to launching the Kostaive COVID-19 vaccine in Japan, with ongoing work on variant protection and influenza vaccine. The company has been able to consistently derive research revenues, maintaining liquidity and avoiding debt, with potential for significant revenue from vaccine orders. Valuation suggests Arcturus may be undervalued compared to peers, with a revised model showing potential for significant revenue growth by 2026.
- 08/09/2024
|
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2024 Earnings Call Transcript August 5, 2024 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head of IR, Public Relations and Marketing Joe Payne - President and CEO Andy Sassine - CFO Conference Call Participants Joohwan Kim - Canaccord Genuity Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Myles Minter - William Blair Yanan Zhu - Wells Fargo Yigal Nochomovitz - Citigroup Samantha Schaeffer - Cantor Fitzgerald Ed Arce - H.C. Wainwright Yale Jen - Laidlaw & Company Operator Greetings and welcome to Arcturus Therapeutics' Second Quarter 2024 Earnings Call.
- 08/05/2024
|
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
- Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $1.85. This compares to loss of $1.98 per share a year ago.
- 08/05/2024
|
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided corporate updates. “We are pleased to remain on track for our first commercial product launch of Kostaive® in Japan lat.
- 08/05/2024
|
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2024 after the market close on Monday, August 5 and will also host a conference call and webcast at 4:30 pm Eastern.
- 07/18/2024
|
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. “Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical produc.
- 06/20/2024
|
Arcturus: A Hidden Gem In The Biotech Sector
- Arcturus is a top pick in the biotech sector with a strong stock market performance. The company generates revenue from research and development partnerships, which helps conserve cash. The launch of the Kostaive vaccine and other programs are expected to drive revenue growth in the short and long term.
- 06/08/2024
|
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference i.
- 06/07/2024
|
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic t.
- 05/28/2024
|
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
- KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine. The results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were.
- 05/20/2024
|
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences: TIDES USA: Oligonucleotide and Peptide Therapeutics (Presentation) Thursday, May 16, 2024 (4:45 p.m. ET) H.C. Wainwright 2nd An.
- 05/15/2024
|
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
- Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/01/2024
|
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024. Arc.
- 04/25/2024
|
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations & Marketing. Joe Payne - President & Chief Executive Officer Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer & Chief Operating Officer Conference Call Participants Evan Wang - Guggenheim Securities Whitney Ijem - Canaccord Genuity Myles Minter - William Blair Jan Hughes - Wells Fargo Pete Stavropoulos - Cantor Fitzgerald Thomas Yip - H.C.
- 03/07/2024
|
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
- Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $1.69. This compares to earnings of $4.33 per share a year ago.
- 03/07/2024
|
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2023, and provided corporate updates. “I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in.
- 03/07/2024
|
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
- Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
- 03/04/2024
|
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
- While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
- 02/26/2024
|
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference in Miami, on Thursday, March 14, 2024, at 11:45 a.m. Eastern Time. A webcast and repla.
- 02/26/2024
|
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the European Commission (EC), based on a positive opinion issued by the European Medicines Agency (EMA), has granted orphan medicinal product designation for the Com.
- 02/22/2024
|
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
- Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare.
- 02/21/2024
|
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
- We've all heard the story with AI by now, and for good reason. It has massive potential to overhaul almost every aspect of our lives.
- 02/20/2024
|
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
- KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine. ARCT-154 was administered at one-sixth the dose of Comirnaty® (5 μg vs 30 μg, respectively). The new analys.
- 02/05/2024
|
Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
- Arcturus Therapeutics is a biotechnology company specializing in rare and infectious diseases, with approved COVID and influenza vaccines in Japan and the EU. The company is developing game-changing therapies for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis. Despite trading at a slight premium relative to peers, ARCT's investment appeal is supported by its innovative IP, financial health, and clinical trials.
- 02/02/2024
|
Arcturus: H1 2024 Rare Disease Drug Data On Deck
- Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 billion by 2030. Interim results from the phase 2 study, using ARCT-810 for the treatment of patients with OTC Deficiency, are expected in the 1st half of 2024.
- 01/31/2024
|
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
- KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original Wuhan-Hu-1 virus strain, and a superior immune response against Om.
- 12/21/2023
|
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
- With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital ecosystem, society will continue to invest in clinical breakthrough stocks in the hopes of forwarding treatments to vexing conditions and diseases.
- 12/17/2023
|
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
- With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and how we can improve functioning within the body.
- 12/13/2023
|
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.
- 12/04/2023
|
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
- Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
- 11/28/2023
|
From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey
- Arcturus Therapeutics is a biotech firm focused on mRNA vaccine development and delivery technologies. The company's core investment thesis is centered around its cutting-edge research and its ability to derive revenue from its collaborations. The potential approval of its first vaccine will work as a proof-of-concept for its mRNA platform and will likely raise the market expectations.
- 11/17/2023
|
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript
- 11/14/2023
|
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
- These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering excellent and efficient solutions for the health of each one of us.
- 11/14/2023
|
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2023 after the market close on Tuesday, November 14 and will also host a conference call and webcast at.
- 10/25/2023
|
Arcturus: Interim Readout Of Rare Disease Data In Coming Months
- Results from phase 2 study using ARCT-810 for the treatment of patients with Ornithine-Transcarbamylase [OTC] deficiency are expected in the coming months. The Ornithine-Transcarbamylase Deficiency market is expected to reach $930.33 million by 2030. A phase 1 study of ARCT-032 for Cystic Fibrosis was completed and clearance was given to begin a phase 1b study.
- 09/07/2023
|
Arcturus Therapeutics to Attend Upcoming Investor Conferences
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Citi's 18th Annual BioPharma Conference 2023 (Hosting 1x1 meetings) Wednesday, September 6 – 7, 2023 2023 Wells Fargo Heal.
- 08/17/2023
|
New Strong Sell Stocks for August 10th
- ARCT, AVY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2023.
- 08/10/2023
|
Why Shares of Arcturus Therapeutics Dropped on Tuesday
- Arcturus Therapeutics has several collaboration agreements. The company is a clinical-stage biotech.
- 08/08/2023
|
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
- Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.98 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.82 per share a year ago.
- 08/07/2023
|
3 Biotech Stocks to Buy Before the Breakout
- During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirming care.
- 07/28/2023
|
3 Biotech Stocks for Getting Rich in 2023
- The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry's research and development. Large biotech companies such as Johnson and Johnson (NYSE: JNJ ), Merck (NYSE: MRK ), and AbbVie (NYSE: ABBV ) offer investors steady and continual growth as well as decent dividends.
- 07/18/2023
|
Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?
- Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 07/17/2023
|
Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race
- Arcturus Therapeutics is developing mRNA medicines and vaccines for infectious diseases and rare disorders, with a focus on their ARCT-810 candidate for ornithine transcarbamylase deficiency. The company reported strong Q1 2023 financial results, with a significant increase in revenue and a net income of $50.8 million, along with a cash runway projected to last until early 2026. Despite late entry into the COVID-19 vaccine market, Arcturus' focus on rare diseases and their financial health make them an attractive investment opportunity, with a speculative 'Buy' recommendation.
- 06/26/2023
|
Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates
- Arcturus Therapeutics (ARCT) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $2.92 per share. This compares to loss of $1.94 per share a year ago.
- 05/09/2023
|
What To Know About ‘Arcturus': New Covid Variant Causing Pink Eye
- New Covid strain XBB.1.18, nicknamed arcturus, is quickly spreading across the U.S., but experts are warning that pink eye and high fever, two symptoms of the new variant, are particularly present among children.
- 04/27/2023
|
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023.
- 04/26/2023
|
Unlocking Arcturus' Potential And De-Risking Through Partnerships
- Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing valuable experience to the company's pipeline development.
- 04/11/2023
|
Why Arcturus Therapeutics Stock Is Soaring Today
- Arcturus beat expectations with its Q4 results. The company also provided an encouraging update on its pipeline programs.
- 03/29/2023
|
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Neda Safarzadeh - IR Joseph Payne - President & CEO Andrew Sassine - CFO Padmanabh Chivukula - Chief Scientific Officer & Chief Operating Officer Conference Call Participants Seamus Fernandez - Guggenheim Yanan Zhu - Wells Fargo Securities Ashiq Mubarack - Citi Pete Stavropoulos - Cantor Fitzgerald Operator Greetings, and welcome to the Arcturus Therapeutics Fourth Quarter 2022 Financial Update and Pipeline Progress Call. At this time, all participants are in a listen-only mode.
- 03/28/2023
|
Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/28/2023
|
Arcturus' mRNA Platform: The Future Of Quick And Efficient Vaccine Delivery
- Arcturus is revolutionizing biotechnology with its cutting-edge mRNA vaccines and delivery systems. They recently teamed up with CSL Seqirus, a leading player in the flu vaccine industry.
- 02/01/2023
|
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- SAN DIEGO--( BUSINESS WIRE )--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.
- 12/19/2022
|
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Kyle Gutsadt - Investor Relations Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Padmanabh Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Seamus Fernandez - Guggenheim Yigal Nochomovitz - Citi Pete Stavropoulos - Cantor Fitzgerald Yale Jen - Laidlaw and Company Yanan Zhu - Wells Fargo Securities Operator Good day ladies and gentlemen and welcome to the Arcturus Therapeutics Third Quarter 2022 Earnings Call. Today's conference is being recorded.
- 11/09/2022
|
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2022
|
Arcturus Therapeutics to Present at the Following Investor Conferences in November
- SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.
- 11/07/2022
|
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
- Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 11/04/2022
|
Why Arcturus Therapeutics Stock Is Skyrocketing Today
- Investors are applauding Arcturus' collaboration with CSL.
- 11/02/2022
|
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
- A strategic collaboration has today's traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a wide variety of applications.
- 11/02/2022
|
Arcturus Therapeutics to Attend the Following Investor Conferences
- SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences. Jefferies Cell and Genetic Medicine Summit (Attending) Thursday – Friday, September 29 – 30, 2022 Cantor Neurology &am
- 09/27/2022
|
7 Small-Cap Stocks to Buy on the Dip or You'll Be Kicking Yourself Later
- With several worrying developments domestically and internationally, many investors chose to rush for the exits, though a brave few may have opportunities in small-cap stocks to buy on the dip. Tethered to small-capitalization companies, these market ideas don't always grab the spotlight.
- 09/22/2022
|
Acrturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2022 Results - Earnings Call Transcript
- Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - Chief Scientifc Officer and Chief Operating Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Nick Abbott - Wells Fargo Kumaraguru Raja - Brookline Capital Markets Yale Jen - Laidlaw and Company Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Operator Good day and welcome to the Arcturus Therapeutics Second Quarter 2022 Financial Update and Pipeline Progress Call. Today's conference is being recorded.
- 08/09/2022
|
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2022
|
Arcturus: Potential Based On Rare Disease Therapy ARCT-810
- An EUA for ARCT-154 as a COVID-19 vaccine in Vietnam has been submitted, with expected approval in 2022. A phase 2 study using ARCT-810 as a treatment option for patients with OTC deficiency is expected to start in mid-2022; results are then expected 2nd half of 2022.
- 06/06/2022
|
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q1 2022 Results - Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2022 Results Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Deepankar Roy - Senior Director, Investor Relations Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Partners Nick Abbott - Wells Fargo Securities Yigal Nochomovitz – Citigroup Kumaraguru Raja - Brookline Capital Markets Steven Seedhouse - Raymond James & Associates Thomas Yip - H.C. Wainwright & Co. Operator Good day.
- 05/09/2022
|
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
- Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months after a low-dose (5 mcg) booster. The study also exhibited that booster vaccination generated.
- 05/05/2022
|
Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space
- Phase 3 pivotal study succeeds in endpoints using ARCT-154 for Covid-19; Emergency Use Authorization submitted to Vietnam with possible approval for use in coming weeks/months. Ability to expand ARCT-154 in the Covid-19 booster treatment market space; Company already received feedback from several regulators for such a pivotal booster study for Covid-19.
- 04/25/2022
|
Raymond James analyst doesn't expect Arcturus' COVID-19 vaccine to be authorized in the U.S.
- Shares of Acturus Therapeutics Holdings Inc. ARCT, -1.43% were down 2.3% in trading on Wednesday after the company said two doses of its experimental COVID-19 vaccine had an efficacy rate of 55% against infection. The Phase 3 clinical trial evaluated the vaccine in 19,000 people in Vietnam; it also found that the investigational shot had an efficacy rate of 95% against severe disease.
- 04/20/2022
|
Arcturus Therapeutics (ARCT) Surges 7.2%: Is This an Indication of Further Gains?
- Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/21/2022
|
Could Arcturus Therapeutics Be the Next Moderna?
- It's not likely, but it could still end up being a good investment.
- 03/01/2022
|
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2021 Results - Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
- Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/21/2022
|
Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses
- Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern. Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) Comirnaty immunization, demonstrated robust antibody responses.
- 01/24/2022
|
Why Arcturus Therapeutics Stock Was Up 16% Thursday
- The biotech stock climbed more than $5 a share in early trading Thursday.
- 12/16/2021
|
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs
- Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying mRNA vaccine candidates for COVID-19. ARCT-154 and ARCT-165 are being studied in a Phase 1/2 trial in U.S. and Singapore.
- 12/16/2021
|
Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock?
- Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.
- 12/10/2021
|
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -46.43% and -90.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2021
|
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
- Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/01/2021
|
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2021 after the market close on Monday November 8, and will also host a conference call and webcast at
- 10/25/2021
|
Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
- The company disappointed last year, but things may be turning around.
- 10/15/2021
|
After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?
- Three healthcare giants are vying for the prize.
- 10/04/2021
|
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
- 09/22/2021
|
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine
- 09/22/2021
|
Arcturus Therapeutics Presents Specific Asian COVID-19 Opportunity
- The company has a specific opportunity to be a vaccine supplier within Asia and to the world.
- 09/10/2021
|
7 Busted Biotech Stocks Due for a Rebound
- Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace.
- 09/08/2021
|
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
- 09/07/2021
|
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More
- With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.
- 08/10/2021
|
ARCT Stock Price Increases Over 35% Pre-Market: Why It Happened
- The stock price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) increased by over 35% pre-market. This is why it happened.
- 08/10/2021
|
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2021 Results - Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -4.02% and -27.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Earnings Previews: AMC, New Oriental Education and 3 Cathie Wood Picks
- More than a third of earnings reports released Friday morning failed to meet consensus estimates for profits, revenues or both.
- 08/06/2021
|
Why Arcturus Therapeutics Stock Is Soaring Today
- The company received a green light to advance two COVID-19 vaccine candidates into clinical testing in a second country.
- 08/03/2021
|
ARCT Stock Price Increases Over 6% Pre-Market: Why It Happened
- The stock price of Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) increased by over 6% pre-market. This is why it happened.
- 08/03/2021
|
Earnings Preview: Arcturus Therapeutics (ARCT) Q2 Earnings Expected to Decline
- Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/02/2021
|
Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam
- Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has collaborated with Vinbiocare to establish a manufacturing facility in Vietnam for its investigational COVID-19 vaccines for sale and use within Vietnam. Under the terms of the arrangement, Vinbiocare will, with consultation from Arcturus, build out a manufacturing facility in Vietnam.
- 08/02/2021
|
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19
- 08/02/2021
|
Can Last Year's Biggest Vaccine Stocks Crush the Market Again?
- These players delivered triple- and quadruple-digit gains.
- 08/02/2021
|
Arcturus Therapeutics Holdings' (ARCT) CEO Joseph Payne on Q1 2021 Results - Earnings Call Transcript
- Arcturus Therapeutics Holdings' (ARCT) CEO Joseph Payne on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -85.34% and -27.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2021
|
Arcturus Therapeutics: Q1 Earnings Insights
- Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 220.90% over the past year to ($2.15), which missed the estimate of ($1.25).
- 05/10/2021
|
Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
- 05/03/2021
|
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
- Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2021
|
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2020 Results - Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
Earnings Preview: Arcturus Therapeutics (ARCT) Q4 Earnings Expected to Decline
- Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/22/2021
|
Arcturus Therapeutics, Chesapeake Energy, Square, and More Wednesday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets were trading mixed.
- 02/17/2021
|
What's in the Cards for Arcturus (ARCT) This Earnings Season?
- Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.
- 02/17/2021
|
Arcturus Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BioCEO--Arcturus Therapeutics to Present at Upcoming Investor Conferences
- 02/11/2021
|
Beat Your Portfolio Fatigue by Dumping These Toxic Stocks
- Stocks without sturdy fundamentals are toxic for your portfolio. Identifying such bloated stocks accurately and dumping them at the right time can protect your returns.
- 02/03/2021
|
Arcturus Therapeutics Is A Worthwhile Bet As The Next Blockbuster COVID-19 Vaccine Play
- ARCT peaked and then slumped in recent weeks as investors lost interest in its coronavirus vaccine. Promising platform and advantages suggests this is a worthwhile holding.
- 01/26/2021
|
McDonald's, Qualcomm, Starbucks, Tesla and More Tuesday Afternoon Analyst Calls
- With the trading day about half over, the broad markets were pushing higher on Tuesday The S&P 500 and Dow Jones industrial average were both up fractionally, and the Nasdaq posted the largest gain, closer to 1%.
- 01/19/2021
|
Is Arcturus Therapeutics a Buy?
- Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.
- 01/12/2021
|
ARCT Stock Price Increased Over 50% This Past Week: Why It Happened
- The stock price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) increased by over 50% this past week as it went from $46.28 on January 4 morning to $73.58 (as of 10:56 AM ET today). This is why it happened.
- 01/08/2021
|
Nasdaq Hits 13,000 for the First Time: ETFs to Bet On
- The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.
- 01/08/2021
|
Why Arcturus Therapeutics Stock Skyrocketed Today
- One Wall Street analyst is very bullish about the biotech's prospects.
- 01/07/2021
|
Why Teladoc Health, Arcturus And Meridian Are Moving Today
- Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases.
- 01/07/2021
|
Domino's, FedEx, Lockheed, Roku and More of Tuesday Afternoon's Analyst Calls
- Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.
- 01/07/2021
|
Did You Miss Out on the Chance for Big Gains from Arcturus Stock?
- The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.
- 01/06/2021
|
Arcturus Therapeutics to Present at Upcoming Investor Conference
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BiotechShowcase--Arcturus Therapeutics to Present at Upcoming Investor Conference
- 01/06/2021
|
Why Is Everyone Talking About Arcturus Therapeutics Stock?
- This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.
- 01/05/2021
|
Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidate
- Shares of Arcturus Therapeutics Holdings Inc. gained 3.7% in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 clinical trial for its COVID-19 vaccine candidate. Arcturus last week announced disappointing data from the Phase 1/2 trial conducted in Singapore that sent the stock tumbling 55%.
- 01/04/2021
|
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
- 01/04/2021
|
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
- Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
- 12/31/2020
|
These Were the 5 Top Genetics Stocks of 2020
- Investors in fast-moving biotechs made out like bandits.
- 12/31/2020
|
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results
- Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
- 12/30/2020
|
Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #CFTR--Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
- 12/30/2020
|
Markets Ease Lower as Arcturus, Blink Charging Plunge
- Two top performers fell back to earth on Tuesday.
- 12/29/2020
|
Arcturus Reports Results From Early-Stage Testing of Its Coronavirus Vaccine
- Investors obviously considered these to be underwhelming, however.
- 12/29/2020
|
Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates (ARCT)
- Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021 on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies. Barclays called the interim data of the vaccine candidate "disappointing," according to a report cited by Seeking Alpha. Analyst Gena Wang wrote that higher dose animal studies showed some efficacy, but "safety concerns limited further dose escalation." The firm downgraded its rating for Arcturus from "overweight" to "equal weight." Barclays holds a price target of $46 for the stock. Raymond James also downgraded its rating from "outperform"to "market perform," while Baird analysts downgraded the stock from "outperform" to "neutral" and lowered its price target from $79 to $69.
- 12/29/2020
|
Why Arcturus Therapeutics Stock Is Plunging Today
- The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate.
- 12/29/2020
|
Why Analysts Lost Confidence in the Arcturus COVID-19 Vaccine
- An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc.
- 12/29/2020
|
Why Shares Of Coronavirus Vaccine Developer Arcturus Are Sinking
- Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares were retreating sharply Tuesday after the company issued an update on its coronavirus vaccine program. What Happened: San Diego, California-based Arcturus announced interim data for a Phase 1/2 study of its vaccine candidate ARCT-021 that shows a favorable safety profile and a less favorable immunogenicity data.
- 12/29/2020
|
Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed ‘underwhelming'
- Investors respond to results from a Phase 1/2 trial of its COVID-19 vaccine candidate that one analyst said were disappointing.
- 12/29/2020
|
Lemonade Stock Gains, Arcturus Therapeutics Tumbles as Market Rally Continues
- The Dow Jones Industrial Average was on the rise Tuesday after House Democrats passed a version of the fiscal stimulus bill that includes larger payments to households.
- 12/29/2020
|
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Received Approval from Singapore HSA to Proceed with Phase 2 Study of its Vaccine Candidate & Provides New/Updated Clinical/Preclinical Data
- 12/28/2020
|
Why Arcturus Therapeutics Stock Is Sinking Today
- An analyst downgraded the biotech stock.
- 12/23/2020
|
3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now
- Nothing compares to these companies.
- 12/20/2020
|
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
- Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
- 12/18/2020
|
3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic World
- They each have a key competitive edge that could set them apart.
- 12/16/2020
|
These 2 Early-Stage COVID Vaccines Could Be Game-Changers
- The first to market won't necessarily dominate the market over the long run.
- 12/13/2020
|
COVID Vaccine Stock Ideas for Different Investors
- Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.
- 12/13/2020
|
3 Top Coronavirus Stocks to Buy in December
- There's something for every kind of investor with this list.
- 12/13/2020
|
Is It Too Late to Get in on This Millionaire-Maker Stock?
- A biotech that no one has heard of has been making a few investors rich for much of 2020.
- 12/12/2020
|
Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right Now
- This could be the perfect time for aggressive investors to scoop up shares.
- 12/10/2020
|
Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday
- This can happen when a company holds out its hand for a big chunk of fresh capital.
- 12/08/2020
|
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Pricing of $150.15 Million Public Offering of Common Stock
- 12/07/2020
|
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
- SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject t
- 12/07/2020
|
Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch
- Don't be surprised if this small biotech takes off in 2021.
- 12/05/2020
|
Arcturus Therapeutics to Present at Upcoming Investor Conference
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Present at Piper Sandler's 32nd Annual Virtual Healthcare Conference
- 11/30/2020
|
3 mRNA Coronavirus Vaccine Stocks to Check Out That Aren't Pfizer, BioNTech, or Moderna
- Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.
- 11/17/2020
|
Why Arcturus Therapeutics Stock Soared Today
- The biotech reported promising results for its coronavirus vaccine candidate.
- 11/10/2020
|
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Quick Version Earnings Call Transcript
- Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Quick Version Earnings Call Transcript
- 11/09/2020
|
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
- 11/04/2020
|
Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
- SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
- 10/30/2020
|
Béisbol, sóftbol y 5G para todos. T‑Mobile aumenta las donaciones para la Little League® durante la Serie Mundial
- El Un‑carrier está duplicando su compromiso de apoyar a los niños y niñas en momentos difíciles en los que familias de todo el país cuentan con presup
- 10/20/2020
|
Walmart Anuncia Planes para Satisfacer las Necesidades Cambiantes de los Clientes en esta Temporada de Compras para las Fiestas
- Las fiestas han llegado a Walmart y el minorista se ha adaptado para satisfacer la evolución en las necesidades de sus clientes que planean comprar de
- 09/23/2020
|
Coronavirus Vaccine Roundup, Early September
- Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated virus vaccines, and virus-like particles.
- 09/04/2020
|
Arcturus Therapeutics Ltd. (ARCT) Investor Presentation - Slideshow
- The following slide deck was published by Arcturus Therapeutics Holdings Inc. in conjunction with this event..
- 09/03/2020
|
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
- SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health, to supply COVID-19 STARR™ mRNA vaccine candidate (ARCT-021). Delivery to Israel of doses of Arcturus’ COVID-19 vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones. “We are pleased to have executed the definitive supply agreement with the Israeli Ministry of Health. Arcturus is honored to play a key role in Israel’s COVID-19 vaccination strategy. As indicated in a recent press conference on July 23rd, led by Prime Minister Netanyahu, this is considered a significant deal to the government of Israel, providing them rights and access to ARCT-021 and a path to potentially vaccinate a substantial portion of their citizens against coronavirus,” said Joseph Payne, President & CEO of Arcturus. “We value the Israeli Ministry of Health’s commitment to our differentiating STARR™ mRNA vaccine candidate and we look forward to advancing the development of ARCT-021.”Israel is the second country, in addition to Singapore, to reserve supply of the ARCT-021 vaccine. Arcturus is in active discussions with certain government entities in major markets and other parts of the world. With the Company’s manufacturing partners, Arcturus is in the process of manufacturing millions of doses in 2020 and positioned to supply hundreds of millions of doses annually thereafter.For more information about rights and access to Arcturus’ COVID-19 vaccine candidate, ARCT-021, please contact Arcturus at Vax@ArcturusRx.com.About STARR™ Technology The STARR™ Technology platform combines self-replicating RNA with LUNAR®, a leading nanoparticle delivery system, into a single solution to produce proteins inside the human body. The versatility of the STARR™ Technology affords its ability upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. The self-replicating RNA-based therapeutic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens. This combination of the LUNAR® and STARR™ technology is expected to provide lower dose requirements due to superior immune response, sustained protein expression compared to non-self-replicating RNA-based vaccines and potentially enable us to produce vaccines more quickly and simply.About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com.Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company’s efforts to develop a vaccine against COVID-19, and therapeutic potential thereof, based on the Company’s mRNA therapeutics, the ability of the Company to scale up manufacturing of vaccine doses, regulatory approval of the vaccine against COVID-19, the potential supply of the vaccine to government entities in major markets and other parts of the world and the impact of general business and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. No assurances can be given that any results reported in pre-clinical studies can be replicated in further studies or in human beings, or that a vaccine can or will ever be developed or approved using the Company’s technology. A more fulsome description of the definitive supply agreement will be included with the current report on Form 8-K to be filed by the Company with the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.IR and Media Contacts Arcturus Therapeutics Neda Safarzadeh (858) 900-2682 IR@ArcturusRx.comKendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008 ctanzi@kendallir.com
- 08/18/2020
|
Why Pfizer's 4% Yield Is Your Best Covid-19 Vaccine Play
- I demonstrate why Pfizer is the best choice for dividend investors playing the Covid-19 vaccine theme.
- 08/13/2020
|
SG Americas Securities LLC Buys Shares of 7,380 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
- SG Americas Securities LLC purchased a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,380 shares of the biotechnology company’s stock, valued at approximately $345,000. Several other hedge funds also […]
- 08/11/2020
|
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
- Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that all subjects in the first cohort have been dosed in the Phase 1/2 clinical study with its ARCT-021 investigational vaccine for COVID-19. The study is being conducted with CTI Clinical Trial and Consulting Services, a global CRO, and in collaboration with Duke-NUS Medical School in Singapore.“We are very pleased to have initiated dosing in our ARCT-021 Phase 1/2 study, and in fact, we have already completed dosing of all subjects in the first cohort of the study. Based on preclinical immunogenicity data, our self-replicating mRNA-based investigational vaccine could have a highly differentiated safety and efficacy profile, and may potentially allow vaccination at very low doses, and with a single administration. These favorable attributes could greatly facilitate mass vaccination campaigns necessary to control this global pandemic,” said Joseph Payne, President & CEO of Arcturus. “We look forward to sharing initial clinical data from this Phase 1/2 study in Q4 which we expect to enable dose selection for late phase clinical trials.”The ARCT-021 Phase 1/2 study includes two parts. In Phase 1, escalating doses will be administered as a single injection to younger adults aged 21 to 55 years old. Based upon the safety, immunogenicity and T-cell response data from this group, dose regimens will be selected for further evaluation in Phase 2 which includes cohorts in younger adults and older adults aged 56 to 80 years old. The study is listed with ClinicalTrials.gov Identifier: NCT04480957.ARCT-021 preclinical data has shown highly promising results with 100% seroconversion for neutralizing antibodies after a single administration using a very low 2 µg dose. Neutralizing antibodies continued to increase for 60 days after dosing. Preclinical results also demonstrated robust CD8+ T-cell Induction and a Th1 biased T-helper cellular immune response. The ARCT-021 vaccine candidate is devoid of viruses and does not utilize viral vectors or adjuvants. ARCT-021 utilizes Arcturus’ self-transcribing and replicating (STARR™) mRNA technology and is delivered with Arcturus’s proprietary LUNAR® lipid-mediated delivery system.About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.comForward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the likelihood of success, efficacy or safety of ARCT-021 as a vaccine against COVID-19 and therapeutic potential thereof based on the Company’s mRNA therapeutics, the timing of the release of ARCT-021 clinical data for human trials of a vaccine against COVID-19, the likelihood that ARCT-021 preclinical data will be predictive of clinical data, the expected dose size and required number of doses of ARCT-021 that may be approved for use by any applicable regulatory authority and the impact of general business and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.IR and Media Contacts Arcturus Therapeutics Neda Safarzadeh (858) 900-2682 IR@ArcturusRx.comKendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008 ctanzi@kendallir.comClinical Site Contact Email: imu@singhealth.com.sg Phone: 6323 7544/8318 0685
- 08/11/2020
|
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Misses Revenue Estimates
- Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -3.77% and -54.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2020
|
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
- COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency, Phase 1 healthy volunteer study continues to advance, initial results expected Q4Successfully raised approximately $280 million in gross proceeds through two public equity offerings in 2020 to advance promising clinical stage pipelineInvestor Conference Call at 4:30 p.m. ET TodaySAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the quarter ended June 30, 2020, and provided a corporate update.“Arcturus has made substantial recent corporate progress highlighted by the advancement of two of our programs, ARCT-021 and ARCT-810, into clinical studies. ARCT-021 has the potential to be an effective and safe vaccine for COVID-19 with a differentiated profile characterized by a very low dose, and a single shot administration. We have also continued to advance our Phase 1 ARCT-810 clinical study in healthy volunteers. ARCT-810 is being developed for ornithine transcarbamylase (OTC) deficiency, a serious disease with limited treatment options. We look forward to obtaining clinical data from both of these important programs this year,” said Joseph Payne, President & CEO of Arcturus.Recent corporate highlights * ARCT-021 program update: Phase 1/2 study with ARCT-021, COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19), which is being conducted in collaboration with Duke-NUS Medical School and performed in Singapore, has initiated and commenced screening subjects. Dosing of the first subject anticipated imminently. Arcturus has provided preclinical data demonstrating a robust cellular (CD8+ cells) and balanced (Th1/Th2) immune response following ARCT-021 administration. Data demonstrate a strong antibody response (anti-spike protein IgG and 100% virus neutralization) at a very low vaccine dose, and a single administration. Neutralizing antibody levels continue to increase out to 60 days post administration. Preclinical data indicate that ARCT-021 is effectively activating the two important components of the adaptive immune response, providing strong support for the ongoing clinical program. * The Company continues to advance its ARCT-021 manufacturing activities. With the Company’s manufacturing partners, Arcturus is positioned to manufacture millions of doses in 2020 and potentially hundreds of millions of doses annually thereafter. * Executed binding term sheet with the Israeli Ministry of Health to supply ARCT-021. A definitive supply agreement is expected shortly. Israel is the second country, in addition to Singapore, to reserve supply of ARCT-021 from the Company. * Announced the formation of a vaccine platform Scientific Advisory Board. The SAB includes renowned experts in virology, infectious disease, vaccine development and public health. * Initiated a Phase 1 study with ARCT-810, a mRNA-based therapeutic candidate for ornithine transcarbamylase (OTC) deficiency (LUNAR-OTC). The ARCT-810 program is supported by preclinical data in OTC deficiency murine models demonstrating that dosing of ARCT-810 results in robust OTC protein expression and improvements in ureagenesis and plasma ammonia, and increased survival. The Company expects to obtain initial Phase 1 healthy volunteer study data in Q4 2020. The phase 1b study in patients has, like many other studies, been affected by the COVID situation, but remains on track to dose by end of year. * Successfully raised approximately $280 million in gross proceeds through public equity offerings in 2020 to date. The Company intends to use the net proceeds of the offerings to develop, test and manufacture the Company’s LUNAR-COV19 vaccine candidate and to continue clinical development of LUNAR-OTC; to advance the Company’s LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical development; to fund early research and development of novel and proprietary RNA medicines; and for general corporate and working capital purposes.Financial results for the quarter ended June 30, 2020 Revenues in conjunction with strategic alliances and collaborations: Arcturus’ primary source of revenues is from license fees and collaborative payments received from research and development arrangements with pharmaceutical and biotechnology partners. For the three months ended June 30, 2020, the Company reported revenue of $2.3 million, compared with $10.2 million in the three months ended June 30, 2019. The decline in collaboration revenues primarily relates to a $3.1 million decrease in reimbursements from CureVac associated with the OTC collaboration that ended in the second quarter of 2019. Additionally, in 2019 we recorded $3.1 million in sublicense revenues related to our agreement with Synthetic Genomics which was a one-time event.Operating expenses: Total operating expenses for the three months ended June 30, 2020 were $12.4 million compared with $10.7 million for the same period of 2019. The current quarter operating expenses were partially offset with $3.8 million of funds earned under the Singapore vaccine grant and $0.9 million in funds awarded by the CF Foundation.Net loss: For the three months ended June 30, 2020, Arcturus reported a net loss of approximately $10.3 million, or ($0.55) per basic and diluted share, compared with a net loss in the three months ended June 30, 2019 of $0.7 million, or ($0.07) per basic and diluted share.Cash, cash equivalents, and investments: Totaled $136.1 million as of June 30, 2020, compared to cash and cash equivalents of $71.4 million at December 31, 2019. Subsequent to the end of the quarter, the Company added net proceeds of $186.3 million from our successful public offering at $53 per share. Our Proforma Cash balance including the public offering, would have been $322.4 million. Based on our current pipeline, the Company’s current cash position is expected to be sufficient to support operations for more than two years. We are currently comfortable with our current cash position and we believe that the Company has the resources needed to drive our pipeline forward to reach several meaningful value creation milestones.Conference Call Monday August 10th @ 4:30 p.m. ET Domestic: 800-754-1346 International: 212-231-2909 Conference ID: 21967092 Webcast: http://public.viavid.com/index.php?id=141066 About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.comForward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding strategy, future operations, collaborations, the likelihood of success efficacy or safety of ARCT-021 or ARCT-810, the ability to initiate or complete preclinical and clinical development programs, including as a result of the COVID-19 pandemic, the supply and delivery of any product or substance, the likelihood that preclinical data will be predictive of clinical data, the ability to enroll subjects therein, the Company’s efforts to develop a vaccine against COVID-19 and therapeutic potential thereof based on the Company’s mRNA therapeutics, the timing of initiation of dosing in human trials of a vaccine against COVID-19, the ability of the Company to scale up manufacturing of vaccine doses, the potential manufacturing capabilities of the Company’s partnership with Catalent, our current cash position and expected cash burn and the impact of general business and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements.
- 08/10/2020
|
Why Earnings Season Could Be Great for Arcturus Therapeutics (ARCT)?
- Arcturus Therapeutics (ARCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/07/2020
|
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer
- Nationally recognized leader in corporate life sciences transactionsSAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Lance Kurata as Chief Legal Officer, starting August 10, 2020. Mr. Kurata joins Arcturus from Mintz, where he was a partner in the Corporate Group and a member of the Life Sciences Practice Group. “Lance is widely recognized as a leading biotechnology focused attorney. His deep expertise in transactions and intellectual property will be particularly valuable as Arcturus continues to drive forward our differentiated messenger RNA therapeutic and vaccine platform and our pipeline of promising investigational medicines. I am very pleased to welcome Lance to the Company,” said Joseph Payne, President & CEO of Arcturus.“I am thrilled to be joining Arcturus during this exciting period of growth. This year, the Company is anticipating clinical trial data from ARCT-021, its COVID-19 vaccine candidate, as well as ARCT-810, an investigational therapy for Ornithine Transcarbamylase (OTC) deficiency. I am looking forward to working with the team to maximize the potential of the Company’s differentiated mRNA based therapeutic modalities,” said Lance Kurata, Chief Legal Officer of Arcturus.Prior to joining Arcturus, Mr. Kurata was Partner and Chair of West Coast Technology Transactions at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC. Mr. Kurata obtained his B.A. from University of California, Los Angeles and he earned his J.D. from Stanford Law School.About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.comForward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding strategy, future operations, collaborations, the likelihood of success efficacy or safety of ARCT-021 or ARCT-810, the ability to initiate or complete preclinical and clinical development programs, including as a result of the COVID-19 pandemic, are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.IR and Media Contact Arcturus Therapeutics Neda Safarzadeh (858) 900-2682 IR@ArcturusRx.comKendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008 ctanzi@kendallir.com
- 08/06/2020
|
With Biotech Stocks, Investors Love the Thrill of the Chase
- Individual investors are placing their bets on biotech companies pursuing coronavirus advances. Some invest for fun and profit, while others want to be a part of a historic breakthrough.
- 08/05/2020
|
Novavax Reported Promising Data on Covid-19 Vaccine. Its Stock Fell Anyway.
- Novovax shares have climbed nearly 4,000% so far this year on excitement over the company’s Covid-19 vaccine.
- 08/04/2020
|
Phase 3 Trials And More: Any COVID-19 Data Is Good Data, Even If It's Bad
- MRNA, PFE/BNTX, and AZN are leading the three vaccines in clinical phase 3 trials. Vaccines developed using different vectors have different advantages and disadvantages.
- 08/04/2020
|
7 Growth Stocks to Ride for the Rest of 2020
- Investors can count on these growth stocks to deliver consistent, positive returns for the remainder of this year and beyond.
- 08/04/2020
|
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
- SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2020 after the market close on August 10 and will also provide a corporate overview and financial results by hosting a conference call and webcast at 4:30 pm Eastern Time on Monday, Aug 10, 2020. Monday, August 10th @ 4:30 p.m. ET Domestic: International: Conference ID: Webcast: 800-754-1346 212-231-2909 21967092 http://public.viavid.com/index.php?id=141066 About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.comIR and Media Contact Arcturus Therapeutics Neda Safarzadeh (858) 900-2682 IR@ArcturusRx.comKendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008 ctanzi@kendallir.com
- 08/04/2020
|
Bull Signal Flashing for Moderna Stock Ahead of Earnings - Schaeffer's Investment Research
- Moderna (MRNA) stock just pulled back to a long-term bullish trendline on the charts , and has cheap options to boot
- 08/04/2020
|
-$0.36 Earnings Per Share Expected for Moderna Inc (NASDAQ:MRNA) This Quarter
- Wall Street analysts forecast that Moderna Inc (NASDAQ:MRNA) will report earnings per share (EPS) of ($0.36) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Moderna’s earnings, with the lowest EPS estimate coming in at ($0.53) and the highest estimate coming in at ($0.22). Moderna reported earnings per share of […]
- 08/04/2020
|
Novavax Says Coronavirus Vaccine Generated 'Robust Antibody Responses' In Phase 1 Trial Participants
- Novavax, Inc (NASDAQ: VAX) announced Tuesday its novel coronavirus (COVID-19) vaccine elicited "robust antibody responses" in participants of the Phase 1...
- 08/04/2020
|
Stocks Climb to Start the Month as New Virus Cases Fall
- The Nasdaq Composite is once again leading the major indexes higher. Investors are hoping more news later this week around unemployment could help extend the gains.
- 08/03/2020
|
MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MOR)
- MorphoSys receives FDA approval for Monjuvi. Brigham president tenders resignation from Moderna board after conflict of interest.
- 08/03/2020
|
We Could Know if Moderna’s Covid-19 Vaccine Works by Halloween, Analyst Says
- Jefferies analyst estimates the biotech’s Phase 3 trial has a 65% chance of working.
- 08/03/2020
|
And The COVID-19 Vaccine Winner Is: 'BioNTech SE' (NASDAQ:BNTX)
- The BioNTech/Pfizer team has launched its Phase 2/3 clinical trial in the USA and internationally for its COVID-19 vaccine on July 27, 2020, after excellent Phase 1/2 clinical trial results.
- 08/03/2020
|
Indigo Ag Announces an Additional $360M in Financing, Appoints Stéphane Bancel, Moderna CEO, to Board of Directors
- Indigo Agriculture, a company dedicated to harnessing nature to help farmers sustainably feed the planet, announces the closing of $360M in additional
- 08/03/2020
|
3 Small-Cap Coronavirus Stocks That Could Skyrocket
- There are many small biotechs developing experimental COVID-19 therapies and vaccine candidates. Arcturus' market cap now tops $1 billion. Arcturus announced in March that it was teaming up with Duke-NUS Medical School to develop a COVID-19 vaccine.
- 08/02/2020
|
Navigating The Pandemic And Beyond
- We still expect the economy to remain on a recovery path but it will not be as quick as earlier assumed.
- 08/02/2020
|
'Be Wary Of Cashing In': Stock Market Update For The Week Ahead
- The Past Week, In A Nutshell
What Happened: Stocks closed the week practically unchanged after mixed reactions to a slew of blow-out earnings results.
Remember This: “...
- 08/02/2020
|
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- SAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced the closing on July 31, 2020 of its previously announced underwritten public offering of 3,753,773 shares of its common stock at a public offering price of $53.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions. Arcturus received total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) of approximately $200 million. The Company intends to use the net proceeds of the offering to develop, test and manufacture the Company’s LUNAR-COV19 vaccine candidate and to continue clinical development of LUNAR-OTC; to advance the Company’s LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical development; to fund early research and development of novel and proprietary RNA medicines; and for general corporate and working capital purposes. Citigroup, Guggenheim Securities and Barclays acted as joint book-running managers for the offering. Baird, B. Riley FBR and H.C. Wainwright & Co. acted as co-lead managers for the offering. Ladenburg Thalmann acted as co-manager for the offering.The securities described above were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-238139) previously filed with the Securities and Exchange Commission (“SEC”) on May 8, 2020 and declared effective by the SEC on May 21, 2020.A final prospectus supplement relating to the offering dated July 28, 2020 was filed with the SEC on July 30, 2020 and is available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Citigroup Global Markets Inc., Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (800) 831-9146; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Barclaysprospectus@broadridge.com, telephone: (888) 603-5847.This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic candidates includes programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for SARS-CoV-2. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.comForward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company’s expected performance, development of any specific novel mRNA therapeutics, satisfaction of the customary closing conditions to the offering, delays in obtaining required stock exchange or other regulatory approvals, stock price volatility, the impact of general business and economic conditions, the expected gross proceeds from the offering and the intended use of proceeds of the offering, are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.IR and Media Contacts Arcturus Therapeutics Neda Safarzadeh (858) 900-2682 IR@ArcturusRx.comKendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008 ctanzi@kendallir.com
- 07/31/2020
|
Do Institutions Own Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares?
- A look at the shareholders of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) can tell us which group is most...
- 07/31/2020
|
Glaxo and Sanofi Will Sell 100 Million Covid-19 Vaccine Doses to the U.S. for Less Than $10.50 Each
- The deal appears to price the vaccine at less than $10.50 a dose.
- 07/31/2020
|
Moderna Targeted By Chinese Hackers For Data Theft: Report
- Moderna Inc (NASDAQ: MRNA), which commenced a late-stage trial of its mRNA vaccine, codenamed mRNA-1273, against SARS-CoV-2 earlier in the week, has been reportedly targeted...
- 07/31/2020
|
Moderna board member resigns to prevent perception of conflict of interest in vaccine trial
- Shares of Moderna Inc. undefined were down 0.2% in trading on Thursday after the market closed when it said a board member had resigned to avoid the...
- 07/30/2020
|
Moderna Stock: How Best to Profit From This Pharmaceutical Stock
- Moderna stock has had one of the best times of any stock in 2020, but the future is growing more uncertain for the company as the COVID-19 vaccine continues to undergo trials.
- 07/30/2020
|
August Outlook: Politics Likely To Be In Play As New Month Gets Started
- Some say never bring up politics. Looking ahead to August on Wall Street, though, it’s hard to avoid.
Entering the month, the big question is whether Congress and the White...
- 07/30/2020
|
Stocks making the biggest moves in the premarket: Boeing, GE, GM, Spotify, Eastman Kodak & more
- The stocks making the biggest moves in premarket trading include Boeing, GE, GM, Spotify, Eastman Kodak, and more.
- 07/29/2020
|
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
- SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 3,264,151 shares of its common stock at a public offering price of $53.00 per share. The gross proceeds of the offering to the Company are expected to be approximately $173.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 31, 2020, subject to the satisfaction of customary closing conditions.Citigroup, Guggenheim Securities and Barclays are acting as joint book-running managers for the offering. Baird, B. Riley FBR and H.C. Wainwright & Co. are acting as co-lead managers for the offering. Ladenburg Thalmann is acting as co-manager for the offering.The Company intends to use the net proceeds of the offering to develop, test and manufacture the Company’s LUNAR-COV19 vaccine candidate and to continue clinical development of LUNAR-OTC; to advance the Company’s LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical development; to fund early research and development of novel and proprietary RNA medicines; and for general corporate and working capital purposes.The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-238139) previously filed with the Securities and Exchange Commission (“SEC”) on May 8, 2020 and declared effective by the SEC on May 21, 2020.A preliminary prospectus supplement relating to the offering was filed with the SEC on July 28, 2020 and is available on the SEC’s website at http://www.sec.gov. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and also will be available on the SEC’s website. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that the Company has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about the Company and the offering. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, from Citigroup Global Markets Inc., Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (800) 831-9146; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Barclaysprospectus@broadridge.com, telephone: (888) 603-5847.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic candidates includes programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for SARS-CoV-2. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com.Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company’s expected performance, development of any specific novel mRNA therapeutics, satisfaction of the customary closing conditions to the offering, delays in obtaining required stock exchange or other regulatory approvals, stock price volatility, the impact of general business and economic conditions, the expected gross proceeds from the offering and the intended use of proceeds of the offering, are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.IR and Media Contacts Arcturus Therapeutics Neda Safarzadeh (858) 900-2682 IR@ArcturusRx.comKendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008 ctanzi@kendallir.com
- 07/29/2020
|
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 28)
Axonics Modulation Technologies Inc (NASDAQ: AXNX)
Capricor Therapeutics Inc (NASDAQ: CAPR)
Fulgent Genetics Inc...
- 07/29/2020
|
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
- SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering. Citigroup, Guggenheim Securities and Barclays are acting as joint book-running managers for the offering.The Company intends to use the net proceeds of the offering to develop, test and manufacture the Company’s LUNAR-COV19 vaccine candidate and to continue clinical development of LUNAR-OTC; to advance the Company’s LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical development; to fund early research and development of novel and proprietary RNA medicines; and for general corporate and working capital purposes.The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-238139) previously filed with the Securities and Exchange Commission (“SEC”) on May 8, 2020 and declared effective by the SEC on May 21, 2020.The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained, when available, from Citigroup Global Markets Inc., Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (800) 831-9146; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Barclaysprospectus@broadridge.com, telephone: (888) 603-5847.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic candidates includes programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for SARS-CoV-2. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, Catalent Inc., and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.comForward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company’s expected performance, development of any specific novel mRNA therapeutics, statements regarding the timing and success of the proposed offering, the anticipated use of proceeds for the proposed offering, satisfaction of the customary closing conditions of the offering, delays in obtaining required stock exchange or other regulatory approvals, stock price volatility and the impact of general business and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.IR and Media Contacts Arcturus Therapeutics Neda Safarzadeh (858) 900-2682 IR@ArcturusRx.comKendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008 ctanzi@kendallir.com
- 07/28/2020
|
MRNA Stock Jumps 9%, Moderna Gets $472M for Vaccine Research
- Moderna has got nearly $1B in support from the U.S. government so far to support the development of the COVID-19 vaccine, MRNA is up.
- 07/28/2020
|
Biotech Bonanza - Second Half Outlook
- Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates an ideal environment for biotechs to continue outperforming the market.
- 07/28/2020
|
The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
- 07/28/2020
|
Coronavirus update: U.S. counts more than 1,000 fatalities for a fourth straight day as virus spread accelerates in South and West
- The coronavirus illness COVID-19 claimed another 1,100 lives in the U.S. in a single day to push the death toll above 145,000 on Saturday, marking a fourth...
- 07/25/2020
|
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
- Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) * Abbott Laboratories (NYSE: ABT) * ABIOMED, Inc. (NASDAQ: ABMD) * Acceleron Pharma Inc (NASDAQ: XLRN) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * Arbutus Biopharma Corp (NASDAQ: ABUS)( won a patent challenge brought about by Moderna Inc (NASDAQ: MRNA)) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Champions Oncology Inc (NASDAQ: CSBR) * Fulgent Genetics Inc (NASDAQ: FLGT) * Genocea Biosciences Inc (NASDAQ: GNCA) (reacted to its second-quarter results) * Hologic, Inc. (NASDAQ: HOLX) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Medpace Holdings Inc (NASDAQ: MEDP) * NeoGenomics, Inc. (NASDAQ: NEO) * Penumbra Inc (NYSE: PEN) * Quest Diagnostics Inc (NYSE: DGX) * RENALYTIX AI ADR (NASDAQ: RNLX) (IPOed Friday) * ResMed Inc. (NYSE: RMD) * Silk Road Medical Inc (NASDAQ: SILK) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * West Pharmaceutical Services Inc. (NYSE: WST)(reacted to its second quarter results) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 23) * ALX Oncology Holdings Inc (NASDAQ: ALXO) (IPOed last Friday) * Forma Therapeutics Holdings Inc (NASDAQ: FMTX) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Nkarta Inc (NASDAQ: NKTX) * Chanticleer Holdings (NASDAQ: SONN)Related Link: 5 Coronavirus Stock Valuations Surging During The Pandemic Stocks In Focus Radius Health Out-licenses Breast Cancer Drug For Up To $350M Radius Health Inc (NASDAQ: RDUS) said it has entered into an exclusive global license agreement with the Menarini Group for the development and commercialization of elacestrant, an investigational asset that is currently being evaluated in a Phase 3 study as a hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer.Radius will receive an upfront payment of $30 million and up to $320 million in additional payments based on the successful achievement of future development and sales milestones. The company is also eligible for tiered, low to mid-teen percentage royalty payments on global net sales.In pre-market trading Friday, Radius Health shares were rising 9.36% to $13.90.BioMarin Makes Regulatory Submission For Bone Growth Disorder Drug In Europe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced the submission of a Marketing Authorization Application to the European Medicines Agency for vosoritide, an investigational, once-daily injection analog of C-type Natriuretic Peptide for children with achondroplasia, the most common form of disproportionate short stature in humans.Subject to completion of EMA's validation check, BioMarin said it anticipates the start of the MAA review to commence in August.Novavax Delays Phase 1 Data Readout, Strikes Coronavirus Manufacturing Deal Novavax, Inc. (NASDAQ: NVAX) said it will release the Phase 1 data, which will consist of preliminary immunogenicity and safety results, during the first week of August, as opposed to the earlier timeframe of July. The Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin shortly thereafter, it added.Novavax also announced an agreement with FUJIFILM Diosynth Biotechnologies, a CDMO, to manufacture bulk drug substance for NVX-CoV2373, the former's COVID-19 vaccine candidate. Fujifilm's site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373, the companies said.View more earnings on IBBThe stock was slipping 4% to $134 in pre-market trading.Arcturus Announces Preliminary Deal to Supply Covid-19 Vaccine Candidate to Israel Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced a binding term sheet with the Israeli Ministry of Health to supply its COVID-19 vaccine candidate, LUNAR-COV19. The parties intend to finalize a comprehensive supply agreement within 30 days, the company said.Earnings LeMaitre Vascular Inc's (NASDAQ: LMAT) second-quarter sales fell a smaller than expected 16% to $24.9 million and EPS fell from 23 cents to 17 cents. The company issued an upbeat guidance for the third quarter.The stock was advancing 12.24% to $32.47 in pre-market trading Friday.Edwards Lifesciences Corp's (NYSE: EW) second-quarter sales fell 15% to $925 million, and adjusted EPS fell 26% to 34 cents. The bottom-line exceeded estimates. The company reiterated its full-year sales guidance of $4 billion to $4.5 billion, and increased its adjusted EPS guidance from $1.58 to $1.75 to $1.75 to $1.95. The sales guidance was in line and the bottom-line guidance exceeded estimates.On The Radar IPOs iTeos Therapeutics, a clinical-stage biopharma engaged in the development of a new generation of highly differentiated immuno-oncology therapeutics for patients, priced its initial public offering, or IPO, of 10.586 million shares at $19.00 per share, above the estimated price range of $16-$18. The shares will begin trading on the Nasdaq under the ticker symbol ITOS. The offering is expected to generate gross proceeds of $201.1 million.Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, priced its IPO of 11 million shares at $19 per share, for generating gross proceeds of $209 million. The company had earlier estimated a price range of $17-$18. The shares will commence trading on the Nasdaq under the ticker symbol NRIX.Inozyme Pharma, Inc, a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, priced its upsized IPO of 7 million shares at $16 per share, for raising gross proceeds of $112 million. The shares are expected to commence trading on the Nasdaq under the ticker symbol INZY.See more from Benzinga * The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results * The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat * The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/24/2020
|
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
- Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced a binding term sheet with the Israeli Ministry of Health to supply the Company’s COVID-19 vaccine candidate, LUNAR-COV19. The parties intend to finalize a comprehensive supply agreement within 30 days.“We are very pleased to support Israel’s vaccination strategy by agreeing to supply our novel self-replicating STARR™ mRNA vaccine candidate. The Arcturus team is working diligently to advance LUNAR-COV19 through clinical development and continues to scale up manufacture for the doses required for global distribution,” said Joseph Payne, President & CEO of Arcturus.Delivery to Israel of doses of Arcturus’ COVID-19 vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones and other conditions to be set forth in the definitive supply agreement. The government of Israel is responsible for distributing the vaccine to its citizens subject to approval by their Ministry of Health.The Israeli Ministry of Health is the second government authority to reserve doses of LUNAR-COV19. Arcturus previously announced its partnership with Duke-NUS in Singapore, in which the Company recently received Clinical Trial Application (CTA) approval to proceed with a Phase 1/2 trial.Arcturus continues to scale up manufacturing to potentially produce hundreds of millions of doses across 2020 and 2021. For more information about rights and access to Arcturus’ COVID-19 vaccine candidate, LUNAR-COV19, please contact Arcturus by email at Vax@ArcturusRx.com.About STARR™ Technology The STARR™ Technology platform combines self-replicating RNA with LUNAR®, a proprietary nanoparticle delivery system, into a single solution to produce proteins inside the human body. The versatility of the STARR™ Technology affords its ability upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. The self-replicating RNA-based therapeutic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens. This combination of the LUNAR® and STARR™ technology is expected to provide lower dose requirements due to superior immune response, sustained protein expression compared to non-self-replicating RNA-based vaccines and potentially enable us to produce vaccines more quickly and simply.About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic candidates includes programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for SARS-CoV-2. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, Catalent Inc., and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com.Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding the Company’s expected performance, the Company’s development of any specific novel mRNA therapeutics, the Company’s efforts to develop a vaccine against COVID-19, and therapeutic potential thereof, based on the Company’s mRNA therapeutics, the ability of the Company to scale up manufacturing of vaccine doses, the timing of the entry into a supply agreement with the State of Israel , the actual entry into a supply agreement with the State of Israel, the expected terms and conditions of the supply agreement with the State of Israel, approval of the vaccine against COVID-19 by the Ministry of Health in Israel and the impact of general business and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings with, or submissions to, the SEC. No assurances can be given that any results reported in pre-clinical studies can be replicated in further studies or in human beings, or that a vaccine can or will ever be developed or approved using the Company’s technology. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.Contact Arcturus Therapeutics Neda Safarzadeh (858) 900-2682 IR@ArcturusRx.comKendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008 ctanzi@kendallir.com
- 07/23/2020
|
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
- Human dosing of LUNAR-COV19 expected soon Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data.
- 07/21/2020
|
Employment recovery falters in virus-ridden states; Trump urges mask use
- The coronavirus has infected more than 14.7 million people around the world as of Tuesday, killing at least 611,322 people.
- 07/21/2020
|
"El mundo está tratando los síntomas de la pandemia, pero no las causas" - BBC News Mundo
- Los gobiernos están respondiendo a la covid-19 como si fuera solo una emergencia médica o un problema económico, pero a menos que veamos cuáles son las fuentes de la crisis habrá más pandemias e incluso peores que la actual, señaló la epidemióloga y veterinaria Delia Grace, autora de un nuevo informe de la ONU.
- 07/21/2020
|
Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Arcturus Therapeutics (NASDAQ:ARCT) Head-To-Head Review
- Aurinia Pharmaceuticals (NASDAQ:AUPH) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Volatility & Risk Aurinia Pharmaceuticals has a beta of 1.3, suggesting that its share price […]
- 07/16/2020
|
All You Need to Know About Arcturus Therapeutics (ARCT) Rating Upgrade to Buy
- Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 07/13/2020
|
Arcturus Therapeutics Holdings Inc. (ARCT): Hedge Funds Sticking Around
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 07/05/2020
|
PETA calls on UNA to stop using live lions as mascots
- People for the Ethical Treatment of Animals is calling on the University of North Alabama to end its live mascot program.
- 07/03/2020
|
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
- Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on.
- 07/01/2020
|
Confederate monuments. Past, present and future
- To understand the origins of the UDC’s crusade, it’s important to have a basic grasp on the reality of race relations from the end of the Civil War through the middle of the 20th century.
- 06/30/2020
|
Una, University of North Alabama’s mascot, dies at 17
- The 17-year-old female African lion died "peacefully" after a brief illness.
- 06/30/2020
|
Arcturus Therapeutics to be Added to Russell 2000® Index
- SAN DIEGO, June 29, 2020 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on.
- 06/29/2020
|
Universités. Étudiants internationaux : la pandémie change la donne
- Les pays qui ont montré une bonne gestion de la crise sanitaire se préparent à accueillir davantage d’étudiants étrangers dès 2021. Au palmarès, l’Australie, la Nouvelle-Zélande et le Canada.
- 06/29/2020
|
Coronavirus vaccine may be available only next year: Experts
- Researchers here are less hopeful than a top US expert who said a vaccine could be ready by the end of this year.. Read more at straitstimes.com.
- 06/26/2020
|
Coronavirus vaccine trial could start by August
- Animal studies of a potential COVID-19 vaccine have been so encouraging that researchers plan to speed up testing of the vaccine in humans.
- 06/26/2020
|
Il 1 luglio il seminario di UNA, UPA ed FCP sulle gare media: ecco come partecipare
- L'obiettivo dell'evento è presentare al mercato il protocollo d’intesa per la gestione delle gare media, nato dalla collaborazione delle tre associazioni
- 06/25/2020
|
Coronavirus tightens its grip over Delhi doctors
- Shortage of medical staffers may hit plan to ramp up testing, treatment as coronavirus curve peaks. Meanwhile, health workers are protesting over inadequate safety.
- 06/22/2020
|
NI woman opens up about CF battle and helping others after surviving ICU
- The Newtownabbey woman is giving something back with new clothing brand '65 roses'
- 06/21/2020
|
Since March, Over 1,200 Doctors and Nurses Have Tested Positive for Covid-19 in Delhi’s Major Hospitals
- Gangaram, RML, AIIMS have reported highest cases of novel coronavirus infection among healthcare workers. If other staffers, such as lab technicians, nursing orderlies and sanitation workers are taken into account from some of the institutes, the total number balloons over 2,000, unions and hospital authorities said.
- 06/20/2020
|
Hazel Green’s Gracie Lynn Butler earns Huntsville Region Female Athlete of the Year
- Hazel Green volleyball and tennis player Gracie Lynn Butler named AL.com Huntsville Region Female Athlete of the Year.
- 06/19/2020
|
Here’s why the FDA may approve a Covid-19 vaccine before the November elections, according to Jefferies’ biotech-research team
- If true, any approval may not actually benefit a vaccine company, but instead other parts of the stock market.
- 06/19/2020
|
Delhi hospitals sound alarm, one goes to police as nurses strike, quit
- Earlier this week, Primus Super Speciality Hospital lodged a complaint with the district authorities and police against its nurses, accusing them of “abandoning patients”.
- 06/18/2020
|
Duke-NUS may bring forward human trials of vaccine to August
- Trials of a Covid-19 vaccine being worked on by the Duke-NUS Medical School and American medicine company Arcturus Therapeutics have "exceeded expectations", potentially allowing human trials of it to be brought forward to August.. Read more at straitstimes.com.
- 06/17/2020
|
Coronavirus Global Updates, 17 June: Steroid Dexamethasone approved as COVID-19 treatment in UK
- Global Coronavirus (COVID-19) Cases Updates: The number of coronavirus fatalities in the United States surpassed the number of American military casualties in World War 1. At least five US states are seeing a record rise in cases and hospitalisations as the country accelerates reopening.
- 06/17/2020
|
Mint Lite | Border tensions to hit industry, airlines fly half empty, other news
- A daily wrap of news and views, opinions and talking points, to get you started on your day
- 06/16/2020
|
Recruiting roundup: Thompson players continue to gather plenty of offers, more
- Thompson players head roundup of recent offers to high school state players.
- 06/16/2020
|
Singapore scientists to start human trials of COVID-19 vaccine in August
- SINGAPORE (Reuters) - Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
- 06/16/2020
|
Moderna Is Racing Toward a Covid-19 Vaccine, but the Field Is Getting Crowded
- The biotech’s CEO says vaccine’s efficacy data could come by Thanksgiving. Rival vaccine projects are getting big boosts.
- 06/16/2020
|
What’s dexamethasone, the cheap steroid hailed as ‘big breakthrough’ against Covid
- Amid the race for a vaccine, Dexamethasone, a cheap and widely used steroid, has become the first drug to be able to save the lives of Covid-19 patients.
- 06/16/2020
|
Singapore scientists to start human trials of Covid-19 vaccine in August
- Singapore scientists testing a Covid-19 vaccine from US firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice. More than 100 vaccines are being developed globally, including several already in human trials from the likes of AstraZeneca and Pfizer, to try and control a disease that has infected more than eight million people and killed over 430,000 worldwide.
- 06/16/2020
|
China Expands Lockdowns After Boom In COVID-19 Cases; Singapore To Start Human Trials Of Vaccine In August
- Global pandemic developments are also reported out of Brazil, Russia, India, Germany, Greece and other nations.
- 06/16/2020
|
Andrew Sassine Is The CFO & Director of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) And They Just Picked Up 1.9% More Shares
- Investors who take an interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) should definitely note that the...
- 06/16/2020
|
FACTBOX-Latest on the worldwide spread of the coronavirus
- * EU countries agreed technical standards for interoperability between smartphone apps that track the risk of infections, a step that could help to revive travel and tourism. AMERICAS * The two most populous U.S. states took markedly different approaches to reopening on Monday with New York scolding local governments for not enforcing social distancing and California encouraging counties to restart economies if they met criteria. * U.S. airline passengers who refuse to wear face coverings could be banned from flying under tougher enforcement policies, the industry's main lobby group said.
- 06/16/2020
|
Singapore scientists to start human trials of COVID-19 vaccine in August
- Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
- 06/16/2020
|
Singapore Scientists to Start Human Trials of Covid-19 Vaccine in August
- More than 100 vaccines are being developed globally, including several already in human trials from the likes of AstraZeneca and Pfizer, to try and control a disease that has infected more than 8 million people and killed over 430,000 worldwide.
- 06/16/2020
|
Singapore planning to start human trials of virus vaccine
- Testing using vaccine from US firm Arcturus Therapeutics is set to start in August.
- 06/16/2020
|
Singapore scientists to start human trials of COVID-19 vaccine in August
- Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
- 06/16/2020
|
Singapore scientists to start human trials of COVID-19 vaccine in August
- Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
- 06/16/2020
|
Singapore scientists to start human trials of COVID-19 vaccine in August
- "The most optimistic case is that it's about this time next year, that we will have a vaccine," Ooi said. Ooi is also working on a monoclonal antibody treatment for COVID-19 and will begin safety trials on healthy people this week, before testing on COVID-19 patients in the coming months.
- 06/16/2020
|
Arcturus Therapeutics (NASDAQ:ARCT) Upgraded to “Buy” at BidaskClub
- Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday, BidAskClub reports. Other research analysts have also recently issued research reports about the stock. ValuEngine upgraded shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating in a report […]
- 06/16/2020
|
Singapore scientists to start human trials of COVID-19 vaccine in August
- Singapore scientists to start human trials of COVID-19 vaccine in August
- 06/16/2020
|
Nurses Union Knocks on SC Door, Seeks Directions on PPE, Salaries and Accommodation
- In their intervention application, the nurses' union sought formulation of a national Covid-19 management protocol for addressing the serious concerns relating to imminent and extreme risks to workers throughout the country.
- 06/15/2020
|
Global DNA Vaccine Market Outlook to 2022 - Featuring Bharat Biotech, GlaxoSmithKline & Green Cross Among Others - ResearchAndMarkets.com
|
CDL-BH e Fiemg firmam parceria para ajudar micro e pequena empresa
- A partir desta segunda-feira (15), uma equipe de suporte estar
- 06/14/2020
|
Marktbeeld 12 juni 2020
- Markt Overzicht door Beursbox.nl (Tom Lassing) over: Dow Jones Industrial Average, Unilever NV. Lees Beursbox.nl (Tom Lassing)'s Markt Overzicht op Investing.com.
- 06/12/2020
|
Adam Gilchrist lauds efforts of Indian nurse in Australia amid COVID-19 crisis
- Adam Gilchrist gave a shout-out to Indian nurse Sharon Varghese, who has been working in Wollongong as a care-worker.
- 06/11/2020
|
Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference
- SAN DIEGO, June 11, 2020 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on.
- 06/11/2020
|
Stocks in Europe skid as reversal from rally continues
- European stocks slumped Thursday in early trade, losing ground for a fourth session as traders looked for a new catalyst after the breathtaking rally from...
- 06/11/2020
|
Singapore boosting capacity for fast Covid-19 vaccine production
- Singapore is building up vaccine manufacturing capacity so production can be ramped up quickly and safely once a Covid-19 vaccine is found.. Read more at straitstimes.com.
- 06/05/2020
|
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency
- SAN DIEGO, June 05, 2020 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on.
- 06/05/2020
|
After Plummeting Over 30%, Are Arcturus Therapeutics Shares Still a Good Buy?
- Arcturus Therapeutics' (NASDAQ: ARCT) stock saw deep losses on May 27, in part because of spillover from news about patients in Moderna's (NASDAQ: MRNA) COVID-19 vaccine trial experiencing adverse reactions. Because both companies are working on COVID-19 vaccines, bad news about one affected the other. After these losses, biotech investors are wondering whether it's time to buy on the dip and buckle up for the long haul with Arcturus, or whether it would be more prudent to cut their losses before they deepen.
- 06/04/2020
|
Cramer Shares His Thoughts On UBS, Alteryx And More
- On CNBC's "Mad Money Lightning Round," Jim Cramer said he's not going to recommend Ares Capital Corporation (NASDAQ: ARCC). He doesn't know what are its investments.UBS Group AG (NYSE: UBS) doesn't have a great dividend, said Cramer. He is not a buyer of the stock. He added that Wells Fargo & Co (NYSE: WFC) has a better dividend. He is starting to warm up again to Wells Fargo because it got out of the auto loan business.Cramer believes in RNA technology and he likes Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT). He sees as a speculative stock and he wouldn't commit a lot of capital to it.Alteryx Inc (NYSE: AYX) is a buy, said Cramer.There is too much heavy lifting for Lyft Inc (NASDAQ: LYFT), with problems in cities and COVID-19, explained Cramer.See more from Benzinga * Cramer Gives His Opinion Alteryx, Johnson & Johnson And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/03/2020
|
Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine
- When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
- 05/28/2020
|
Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine
- When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
- 05/28/2020
|
Why Arcturus Therapeutics Stock Is Plunging Today
- Shares of Arcturus Therapeutics (NASDAQ: ARCT) were plunging 32.3% as of 11:43 a.m. EDT on Wednesday. Reports surfaced yesterday that one of the participants in Moderna's phase 1 study of its COVID-19 vaccine candidate experienced a severe reaction. STAT News' Matthew Herper reported on Tuesday that Ian Haydon developed a high fever after receiving a second dose of Moderna's experimental COVID-19 vaccine.
- 05/27/2020
|
New Coronavirus Vaccine To Send Virus' Spike Protein To Activate Body's Immune Response
- Novavax is now beginning its clinical trials.
- 05/26/2020
|
Dal Sasso, Nielsen: «Nel secondo semestre possibile chiusura in pareggio per il mercato» | Engage
- Secondo Dal Sasso di Nielsen, questo porterebbe il settore a chiudere il 2020 in calo a doppia cifra, in vista di un 2021 sicuramente più "effervescente"
- 05/25/2020
|
Nielsen: pubblicità a -9,2% tra gennaio e marzo. La ripresa? Sarà nel secondo semestre | Engage
- Il Covid-19 ha portato il mercato pubblicitario a chiudere marzo a -29% secondo Nielsen. Ma ha anche stimolato un profondo cambiamento nella comunicazione
- 05/25/2020
|
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
- Ultragenyx Pharmaceutical, Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc. (ARCT), a leading messenger RNA medicines company, today announced that Ultragenyx has exercised its option to purchase 600,000 shares of Arcturus common stock at $16.00 per share. “We are encouraged by the advancement of Arcturus’s broad nucleic acid platform across multiple therapeutic areas, including their self-replicating mRNA-based COVID-19 vaccine candidate,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
- 05/21/2020
|
The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 19)
ADC Therapeutics SA (NYSE:...
- 05/20/2020
|
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 18)
ADC Therapeutics SA (NYSE:...
- 05/19/2020
|
Coronavirus: Ever-changing profile of a silent killer with many questions left unanswered
- Why is this virus so much more contagious than Sars? Why do some patients develop a severe form of the disease while others do not?. Read more at straitstimes.com.
- 05/13/2020
|
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
- 05/13/2020
|
Is Arcturus Therapeutics (ARCT) Stock a Solid Choice Right Now?
- Arcturus Therapeutics (ARCT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 05/12/2020
|
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
- 05/12/2020
|
Eli Lilly's Retevmo, And Other News: The Good, Bad And Ugly Of Biopharma
- Eli Lilly's Retevmo gets FDA approval. Arcturus announces positive preclinical data for Covid-19. Quidel's antigen test kit gets FDA approval.
- 05/11/2020
|
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript
- Image source: The Motley Fool. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)Q1 2020 Earnings CallMay 07, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and welcome to the Arcturus Therapeutics conference call.
- 05/10/2020
|
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)
- New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than.
- 05/08/2020
|
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update
- Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19);New preclinical data demonstrate robust immunogenicity with a single, low dose Company remains.
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
- 05/05/2020
|
Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020
- SAN DIEGO, May 04, 2020 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on.
- 05/04/2020
|
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus. LUNAR-COV19 utilizes Arcturus’ self-transcribing and replicating mRNA (STARR™) technology and the Company’s LUNAR® lipid-mediated delivery to produce an extraordinarily low dose, potential single shot COVID-19 vaccine.
- 05/04/2020
|
Medical, tech investments pay off in Covid-19 war
- The world is fighting a war against a virus and Singapore scientists are pulling their weight when it comes to building up an arsenal of knowledge that can be used to vanquish the enemy.. Read more at straitstimes.com.
- 05/02/2020
|
The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs May 1.) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * AstraZeneca plc (NYSE: AZN) (announced an agreement with the University of Oxford for the development of
- 05/01/2020
|
The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs May 1.)
Arcturus Therapeutics Ltd (...
- 05/01/2020
|
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Black Diamond
- 04/29/2020
|
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 28.)
AstraZeneca plc (NYSE:...
- 04/29/2020
|
BBBY, DVAX among premarket gainers
- Broadwind Energy (NASDAQ:BWEN) +60%. on $19M order.TrovaGene (NASDAQ:TROV) +44% on new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avasti
- 04/28/2020
|
10 Biggest Price Target Changes For Tuesday
- HC Wainwright & Co. boosted the price target for Arcturus Therapeutics Ltd (NASDAQ: ARCT) from $26 to $62. Arcturus Therapeutics closed at $30.53 on Monday.
Rosenblatt...
- 04/28/2020
|
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Avadel Pharmaceuticals PLC
- 04/28/2020
|
96 Biggest Movers From Yesterday
- Gainers
Naked Brand Group Limited (NASDAQ: NAKD) shares climbed 60.8% to close at $0.78 on Monday after climbing 8% on Friday.
Yield10 Bioscience, Inc. (NASDAQ: YTEN) shares...
- 04/28/2020
|
Mid-Afternoon Market Update: Dow Surges 350 Points; CNX Midstream Partners Shares Plummet
- Toward the end of trading Monday, the Dow traded up 1.48% to 24126.82 while the NASDAQ rose 1.17% to 8,735.79. The S&P also rose, gaining 1.52% to 2,879.73.
The U.S. is the...
- 04/27/2020
|
AMRN, EPR among top gainers
- Axsome Therapeutics (NASDAQ:AXSM) +44% as Axsome's lead candidate successful in Alzheimer's study.Avadel Pharmaceuticals plc (NASDAQ:AVDL) +34% on positive data on lead drug.Yield10 Bioscience (NASDAQ
- 04/27/2020
|
Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
- 100% of animals seroconverted by day 19 at a low dose (2 µg)LUNAR-COV19 remains on track to initiate human clinical trials this Summer SAN DIEGO, April 27, 2020 -- Arcturus.
- 04/27/2020
|
The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks hitting 52-week highs April 23.) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Cue Biopharma Inc (NASDAQ: CUE) * Eli Lilly And Co (NYSE: LLY
- 04/24/2020
|
The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Arvinas Inc (NASDAQ: ARVN) * Exelixis, Inc. (NASDAQ: EXEL
- 04/22/2020
|
The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 21)
Alnylam Pharmaceuticals,...
- 04/22/2020
|
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced the closing on April 20, 2020 of its previously announced underwritten
- 04/21/2020
|
Bio Roundup: Alnylam's Billions, COVID-19 Vaccines, Moma Debuts & More
- The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn't the only way for biotech companies to
- 04/17/2020
|
Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock
- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced the pricing of an underwritten public offering of 4,117,650
- 04/16/2020
|
The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 15.) * Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) * Calithera Biosciences Inc (NASDAQ: CALA) (provided an update on the impact of COVID
- 04/16/2020
|
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it intends to offer and sell shares of its common stock in an underwritten
- 04/15/2020
|
3 Frontrunners In COVID-19 Vaccine Development: What You Need To Know
- As companies race against time to bring to market a vaccine for the new coronavirus — SARS-CoV-2 — that causes COVID-19, three contenders have emerged as ...
- 04/15/2020
|
Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency
- Clinical Plan Includes Healthy Volunteers in New Zealand and OTC-Deficient Patients Across Several Sites in United States Investor Conference Call at 4:00 pm ET Today SAN.
- 04/13/2020
|
Stocks To Watch: Big Banks And Vaccine Players In The Spotlight
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 04/11/2020
|
Pfizer, BioNTech, Arcturus Share Timelines For Human Testing As COVID-19 Vaccine Development Intensifies
- The enormity of the coronavirus pandemic has forced biopharma companies to step up efforts to expeditiously develop vaccines and treatments for COVID-19. The Frontrunners Moderna Inc (NASDAQ: MRNA), which was the first company to move its coronavirus vaccine candidate to the clinics, said in mid-March
- 04/09/2020
|
Biohaven on go with study of vazegepant in COVID-19 as others take action amid the pandemic
- The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company's (NYSE:BHVN) migraine med vazegepant, a calcitonin gene-related pept
- 04/09/2020
|
Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine
- GMP-Manufactured Batch to be Delivered in June 2020 Human Dosing Expected to Begin in Summer 2020 SAN DIEGO, April 09, 2020 -- Arcturus Therapeutics (the “Company”, NASDAQ:.
- 04/09/2020
|
When Will a Coronavirus Vaccine be Ready? These 9 Programs Are Making Progress.
- A true return to normalcy is unlikely without a widely-available coronavirus vaccine. There are currently at least 47 Covid-19 vaccine programs under way. Here are some to keep an eye on.
- 03/30/2020
|
The race to develop a COVID-19 vaccine
- The race for a coronavirus (COVID-19) vaccine is on in the ugliest of ways. Since December, scientists around the world have been racing to create the first vaccine against COVID-19, with vaccine trials either starting or poised to begin in the US, China and Europe. Be patient, because the process may take up to two years. Vaccines in a pandemic are not a 100 percent solution if they are rushed or, worse, politicized.
- 03/22/2020
|
Australia Will Soon Roll Out Medication Used to Successfully Treat COVID-19 Patients in Secret Trials
- 50 hospitals will try to resolve the best way to use these drugs.
- 03/21/2020
|
The Stock Market Has Tanked: What To Do Next
- Cash and Margin: Be cautious and thoughtful, not fearful and frozen. Housing and Mortgages: Expect transactions to fall off a cliff. The time to refinance is no
- 03/19/2020
|
7 “Perfect 10” Healthcare Stocks to Buy Now
- Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.
- 03/18/2020
|
Global Equities Tumble on Fears Governments Will Need More Stimulus to Battle Coronavirus Effects
- European stock markets and U.S. stocks futures are down sharply on Wednesday, as investors weigh up whether plans by governments to prevent a global recession from the coronavirus would be enough.
- 03/18/2020
|
Mid-Afternoon Market Update: Dow Falls Over 2300 Points; BioNTech Shares Surge
- Toward the end of trading Monday, the Dow traded down 10.19% to 20,822.15 while the NASDAQ fell 9.87% to 7,097.62. The S&P also fell, dropping 9.73% to 7,108.79. South Korea...
- 03/16/2020
|
10 Biggest Price Target Changes For Thursday
- JP Morgan cut Workday Inc (NASDAQ: WDAY) price target from $190 to $175. Workday shares closed at $142.03 on Wednesday.
H.C. Wainwright raised the price target for Arcturus...
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacted to its fourth-quarter results) * Centogene NV (NASDAQ: CNTG) * Tiziana Life Sciences PLC (NASDAQ
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV
- 03/11/2020
|
The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Centogene NV
- 03/06/2020
|
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS
- 03/05/2020
|
H.C. Wainwright Maintains Their Buy Rating on Arcturus Therapeutics (ARCT)
- In a report released today,
Ed Arce
from H.C. Wainwright maintained a
Buy
rating on Arcturus Therapeutics (
ARCT
–
Research Report
), with a price target of
$18.00
. The company’s shares closed last Monday at $17.10, close to its 52-week high of $18.
- 03/04/2020
|
CVS, UNH among premarket gainers
- Cellect Biotechnology (NASDAQ:APOP) +38% on Canndoc deal.Dynatronics (NASDAQ:DYNT) +28%.AIM ImmunoTech (NYSEMKT:AIM) +24% on recent announcements on Covid-19 front.Arcturus Therapeutics Holdings (NASD
- 03/04/2020
|
And the Covid-19 list keeps growing...
- Recent announcements on the COVID-19 front:Luminex (NASDAQ:LMNX): Working on two SARS-Cov-2 tests: NxTAG CoV Expanded Panel: should be available to ship to customers in a few weeks. Testing in China t
- 03/04/2020
|
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
- 02/21/2020
|
Baird likes drug wholesalers in premarket analyst action
- Arcturus Therapeutics (NASDAQ:ARCT) initiated with Buy rating and $19 (70% upside) price target at Guggenheim.BeyondSpring (NASDAQ:BYSI) initiated with Buy rating and $25 (45% upside) price target at
- 02/07/2020
|
How Reginald Ruffin led Miles to Division II playoffs
- The Golden Bears have won four Southern Intercollegiate Athletic Conference titles and twice earned a spot in the NCAA Division II playoffs during Ruffin’s tenure.
- 11/22/2019
|
A Base Editing IPO from Beam Therapeutics
- The ability to modify genes may be one of the most promising disruptive technologies there is today. As the general public learns about the potential of gene editing, retail investors will be looking for stocks that provide some exposure to it. In the case of gene editing, there are three stocks that would be considered pure plays on the theme - at least the last time we checked. That would have been last March when we wrote about A Few Updates on the Progress of Gene Editing noting that 'with patents being filed and issued left and right, it’s also starting to look like there is no
- 10/01/2019
|
De cursos no Senac ao ensino superior: Minas
- Antes de o chef se tornar a estrela dos restaurantes e dos reality shows, Minas Gerais j
- 08/07/2018
|
STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics -
- STORM Therapeutics Exclusive Speaker Interview
- 12/12/2017
|
